The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5 billion. The merger will help Novo meet strong demand for weight-loss drug Wegovy, increasing its filling capacity starting in 2026.
On the charts, CTLT has been chopping higher since mid-November. Today's jump still isn't enough to close its April bear gap, though, which occurred after a Danaher (DHR) takeover fell through. At last glance, CTLT was up 9.7% at $59.79, already sporting a 33.4% lead since the start of 2024.
Catalent stock's typically quiet options pits are buzzing today, with 4.505 calls and 1,212 puts exchanged so far, which is 11 times the average daily options volume already. The February 60 call is the most popular by far, with new positions opening at the February 62.50 call.
It's also worth noting that short interest represents 6.1% of the stock's available float. It would take nearly five days for shorts to cover their bets, at CTLT's average pace of trading.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report
